Principal Research Fellow, Neurodegenerative Diseases
University College London

Dr. Byrne is a Medical Research Council-funded principal investigator whose work focuses on developing sensitive and accessible biofluid biomarkers for Huntington’s disease (HD). During her PhD at UCL, she led the HD‑CSF biofluid collection and published influential research on neurofilament light (NfL) in blood, including a landmark 2017 study that helped establish NfL as a leading biomarker in HD. In 2022, she received a 5‑year MRC Career Development Award to establish her own lab, where she is expanding biomarker research and pioneering new approaches such as remote sample collection and big‑data harmonization, with particular focus on Juvenile‑onset HD.

Alongside her research, Dr. Byrne is an active HD advocate and family member. She serves on the boards of two HD charities and leads JOIN‑HD—the first global registry for Juvenile‑onset HD—to ensure that young people and families are represented and supported in research.

Clinical Research Associate, Barker Group, Brain Repair Centre, University of Cambridge
Honorary Neurology Registrar, Cambridge University Hospitals
Neurology Specialty Doctor, East Suffolk/North Essex Foundation Trust

Dr. Voysey is an academic neurologist based at Cambridge University, UK. Her research focuses on exploring the vicious cycle between sleep dysfunction and neurodegeneration, particularly through translational studies incorporating fluid biomarkers in Huntington’s disease.  She is now Chief Investigator of the DORA-HD Phase II clinical trial, which is due to start in late 2026 and will explore whether treating sleep problems in HD gene carriers can improve clinical outcomes and slow disease progression.